Streamex Announces 2025 Corporate Update Webinar and GLDY Pre-Sale Targeting $100 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Source: Newsfilter
- GLDY Pre-Sale Launch: Streamex initiated the GLDY pre-sale on November 10, 2025, with an initial goal of $100 million and an anticipated launch in Q1 2026, marking a significant step in the monetization and digitization of gold assets.
- Strategic Partnership Expansion: The exclusive three-year partnership with Monetary Metals enables yield-bearing precious metals products offering up to 4% annualized returns, enhancing Streamex's competitiveness in the yield-focused precious metals market.
- Strengthened Capital Position: Entering 2026 with a robust capital foundation, Streamex ensures resources for product development and GLDY expansion over the coming years, improving the company's financial stability and operational flexibility.
- Executive Team Expansion: The company has onboarded several seasoned industry executives, including Chief Investment Officer Mitch Williams, further strengthening its leadership and advisory network to support future strategic initiatives.
Analyst Views on STEX
Wall Street analysts forecast STEX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STEX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.120
Low
12.00
Averages
12.00
High
12.00
Current: 3.120
Low
12.00
Averages
12.00
High
12.00
About STEX
Streamex Corp., formerly BioSig Technologies, Inc., is a real world asset (RWA) tokenization company. The Company with institutional grade infrastructure brings the gold and commodities market on chain, enabled by a gold denominated treasury and tokenization technology powering the modern commodities market. The Company is a wholly owned subsidiary of BioSig Technologies, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
